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Abstract
Background: Despite significant improvements in life expectancy of kidney transplant patients due to advances in surgery
and immunosuppression, Chronic Allograft Nephropathy (CAN) remains a daunting problem. A complex network of cellular
mechanisms in both graft and peripheral immune compartments complicates the non-invasive diagnosis of CAN, which still
requires biopsy histology. This is compounded by non-immunological factors contributing to graft injury. There is a pressing
need to identify and validate minimally invasive biomarkers for CAN to serve as early predictors of graft loss and as metrics
for managing long-term immunosuppression.
Methods: We used DNA microarrays, tandem mass spectroscopy proteomics and bioinformatics to identify genomic and
proteomic markers of mild and moderate/severe CAN in peripheral blood of two distinct cohorts (n=77 total) of kidney
transplant patients with biopsy-documented histology.
Findings: Gene expression profiles reveal over 2400 genes for mild CAN, and over 700 for moderate/severe CAN. A
consensus analysis reveals 393 (mild) and 63 (moderate/severe) final candidates as CAN markers with predictive accuracy of
80% (mild) and 92% (moderate/severe). Proteomic profiles show over 500 candidates each, for both stages of CAN including
302 proteins unique to mild and 509 unique to moderate/severe CAN.
Conclusions: This study identifies several unique signatures of transcript and protein biomarkers with high predictive
accuracies for mild and moderate/severe CAN, the most common cause of late allograft failure. These biomarkers are the
necessary first step to a proteogenomic classification of CAN based on peripheral blood profiling and will be the targets of a
prospective clinical validation study.
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Introduction
Kidney transplantation offers a significant improvement in life
expectancy and quality of life for patients with end stage renal
disease[1]. Unfortunately, a chronic, progressive allograft dys-
function of uncertain etiology continues to be a primary cause of
graft loss[2,3]. There has been some evolution of terminology to
better describe the histological basis of this chronic, progressive
nephropathy, commonly referred to as chronic allograft nephrop-
athy (CAN) and more recently as interstitial fibrosis and tubular
atrophy (IF/TA)[4–6]. Immunologic factors linked to IF/TA are
acute, sub-clinical and chronic rejection, HLA mismatching and
circulating donor-specific anti-HLA antibodies[7,8]. Non-immu-
nologic factors include hypertension, chronic toxicity of calci-
neurin inhibitors, hyperfiltration and diabetes mellitus[9–12]. The
unifying mechanism is thought to be a progressive cycle of vascular
and tissue injury, incomplete repair, compensatory hypertrophy,
progressive interstitial fibrosis and nephron loss[13]. In the present
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6212paper, we will use the term CAN to refer to biopsy-documented
and graded IF/TA in the absence of any other known cause[14].
As early as two years post kidney transplant, protocol biopsies
have shown that more than 50% of recipients have mild
CAN[2,15,16] and by 10 years over 50% of kidney transplant
recipients have severe CAN that is associated with diminishing
graft function[2]. Traditional kidney function measurements like
serum creatinine and glomerular filtration rates used to predict
CAN have poor predictive values[17] and a diagnosis requires a
transplant biopsy[18,19]. While critical to examine structural
changes prior to graft loss, predicting graft outcomes strictly based
on the kidney biopsy is difficult and this invasive procedure has
significant costs and risks for patients. Thus, there is a pressing
medical need to identify minimally invasive biomarkers that are
able to identify early stages of CAN at a time that changes in
therapy may alter outcomes.
Rapidly evolving technologies for genomics have created new
opportunities to develop minimally invasive biomarkers. Recent
studies, including our own, have identified genes that are
differentially expressed at the mRNA level in kidney biopsies in
the presence of CAN[16,20,21]. The limitation of these studies is
that they require an invasive transplant biopsy. Others have
successfully sampled urine and peripheral blood using RT-qPCR
or proteomics to identify small numbers of potential biomarkers
for CAN, though none are validated for clinical use[22,23]. Here
we report a set of unique gene and protein expression-based
signatures for CAN measured in the peripheral blood that directly
addresses the critical medical need for a set of minimally invasive
biomarkers for this devastating and common complication of
kidney transplantation. These signatures have a predictive
accuracy of 80% for mild CAN and 92% for moderate/severe
CAN. This is the first study using whole genome DNA
microarrays and tandem mass spectrometry proteomics to
successfully apply proteogenomics of peripheral blood to clinical
transplantation.
Materials and Methods
Patient Populations
Test Set 1 comprised 42 kidney transplant patients randomized
to either cyclosporine or de novo rapamycin at the Cleveland
Clinic, whose clinical courses have been previously, described
[15,16,24]. Density gradient-purified peripheral blood lympho-
cytes (PBL) were collected at the time of protocol two-year
biopsies. Test Set 2 comprised 35 patients from 3 clinical centers
(St. Vincent’s Medical Center, Scripps Clinic, and Cleveland
Clinic). All patients were on FK506. Whole blood was collected
directly into PaxGene Tubes (PreAnalytix) at the time of biopsies
for suspected CAN or protocol one-year biopsies. All the studies in
this manuscript were covered by Human Subjects Research
Protocols approved by each Center’s Institutional Review Board
and by the IRB of The Scripps Research Institute as the parent
institution. Informed consent was obtained from all study subjects
in the study.
Pathology
Banff IF/TA grades based on tubulointerstitial features were
determined for all patients by kidney biopsies: grade 0 (no
evidence CAN), 1 (mild CAN), and 2 (moderate CAN) and 3
(severe CAN). We merged patients with Banff 2 and Banff 3 IF/
TA to increase numbers. Diagnosis was done first by local
pathologists and reviewed in a blinded fashion by Drs. Kim Solez
(Set 1) and Lillian Gaber (Set 2). C4d staining was only available in
the more recently acquired Test Set 2.
Gene expression profiling and analysis
RNA was extracted from Test Set 1 using Trizol (Invitrogen)
and in Test Set 2 using Paxgene Blood RNA system (PreAnalytix)
and globin transcripts were reduced using GlobinClear (Ambion).
Biotinylated cRNA was prepared using Ambion MessageAmp
Biotin II (Ambion) and hybridized to Affymetrix Human Genome
U133 Plus 2.0 GeneChips. Normalized signals that were generated
using a quantile normalization strategy (RMAExpress[25]) were
used for class comparisons (ANOVA) and class predictions (BRB
Array Tools; http://linus.nci.nih.gov/BRB-ArrayTools.html). We
chose the Diagonal Linear Discriminant Analysis (DLDA) method
for class predictions, which is based on maximum likelihood
discriminant rules that give consistently good results with our data
set and others[26]. Receiver Operating Characteristics (ROC)
analysis was done using JROCFIT (http://www.rad.jhmi.edu/
jeng/javarad/roc/JROCFITi.html). Heatmaps were generated
using Cluster and Treeview[27] and functional analysis was
performed using Gene Ontology (GO) (http://www.geneontology.
org/) and Ingenuity Pathway Analysis (IPA). Consensus analysis
was designed to identify true classifiers in the two independently
collected data sets. Variability between the two test sets within
each class (i.e. Banff 1/Test Set 1 vs. Banff 1/Test Set 2) was
eliminated by removing all genes with a Student’s t-test p-value of
,0.05 after which the remaining genes were used to identify
consensus candidates by class comparisons. All differentially
expressed gene lists are shown in Supplementary Data Tables
S1, S2, S3, S4, S5, S6. All the microarray data for this study is
available for review at the private GEO accession site http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=vbgvzkwugg-
qiqpy&acc=GSE12187.
Shotgun LC/MS/MS proteomics
All protein samples were prepared from density gradient-
purified PBL. Individual patient samples were pooled within each
Test Set (3 samples/pool) based on Banff classifications and pools
were run in triplicates. Total protein was proteolytically digested
with trypsin and samples run using Multidimensional Protein
Identification Tool (MudPIT) protocol as previously described[28]
using an LTQ XL mass spectrometer (ThermoFisher). Raw data
were searched against the EBI-IPI_human_12_01_2006 database
supplemented with a decoy database where each entry of the
original protein contains its reversed sequence. Database searching
used SEQUEST (v27)[29] and outcomes were filtered using
DTASelect[30]. Relative quantifications were done using spectral
counts normalized to the median of the total spectral counts[31].
Pair-wise comparisons between CAN biopsy classes were done by
differentially expressed proteins (Student’s t-test, p#0.05) and as
all-or-none/unique events.
Results
Study Population
Recipients in both Test Sets were sex and age matched (Table 1).
The only significant differences in Test Set 1 were Donor age
between Banff 0 and Banff 1 groups. In Test Set 2 there were
significant differences in induction therapy between Banff 0 and
Banff 1 and between Banff 0 and the Banff 2,3; time to biopsy
between Banff 0 and Banff 1 and between Banff 0 and the Banff
2,3; and steroid use between Banff 0 and Banff 1 and between
Banff 0 and Banff 2,3. Only the Banff 2,3 group in Test Set 2 had
a significantly higher serum creatinine compared to the Banff 0,
thus, renal function levels per se were not a major determinant of
the gene profiles. The higher creatinine levels in the Banff 2,3
group of Test Set 2 most likely reflect the fact that this group was
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PLoS ONE | www.plosone.org 3 July 2009 | Volume 4 | Issue 7 | e6212‘‘biopsy for cause’’, while Test Set 1 were all protocol biopsies
done regardless of any renal function change. However, by design,
the two Test Sets differed significantly in recipient age, HLA
mismatch, induction therapy, clinical center, immunosuppression,
serum creatinines, and time to biopsy.
Gene expression profiling of mild CAN
We performed ANOVA-based class comparisons between
Banff 0 (no histological evidence of CAN) and Banff 1 (mild
CAN). At p-values ,0.005, 1066 genes (1307 probe sets) were
differentially expressed. Annotation of function by Gene
Ontology (GO) shows 8 categories comprised of .25 genes
each (Figure 1A) including 58 genes linked to immunity and
inflammation. IPA shows that these 1066 genes fall into 27
networks with .15 genes per network (Supplementary Data
Table S7). The top network was immune response and two
additional networks in the top 10 were also immune response
with 27 and 22 focus genes, respectively. The top canonical
pathway was Toll-like Receptor Signaling followed by SAPK/
JNK, Apoptosis, Notch and Death Receptor and Interferon
Signaling. Finding 1066 significantly differentially expressed
genes is a first indication that PBL transcript profiling is
capable of classifying subjects defined by CAN biopsy
histology. Class prediction using DLDA demonstrates 90%
mean correct classification[32,33]. Supervised hierarchical
clustering shows misclassification of only 2 samples (Supple-
mentary Figure S1).
Based on gene expression profiles of the whole blood samples in
Test Set 2, there were 1429 genes (1591 probe sets) differentially
expressed at p-values ,0.005. GO annotation of gene functions
revealed the same groups as PBL including 50 immune response
genes (Figure 1B). IPA reveals 30 networks with $15 genes per
network (Supplementary Data Table S8). The top canonical
pathways were: B Cell Receptor, Toll-like Receptor, Death
Receptor, Chemokine, Glucocorticoid Receptor, and IL-4 Sig-
naling. DLDA demonstrates 88% mean correct classification.
Supervised hierarchical clustering shows misclassification of only 1
sample (Supplementary Figure S2).
A consensus analysis for Banff 0 vs. Banff 1 was performed with
these two independently collected data sets by a class comparison
at p-values ,0.005 and identified 393 genes (424 probe sets)
significantly differentially expressed in both data sets. This
‘‘consensus’’ gene list represents the intersection of these two
significantly different test sets classifying mild CAN by blood
transcription profiling. We then combined all the samples of both
Test Sets (n=55) and performed class predictions using the top 50
differentially expressed, consensus genes ranked by p values to
obtain a class prediction accuracy of 80% depicted as a ROC
curve (Figure 2A). Figure 2B shows the heat map classifying Banff
0 vs. Banff 1 using the 50 genes. The importance of the heat map
display is that it provides the reader a clear look at the consistency
of gene expression changes in all the samples studied for both test
sets. It is clear that there are large ‘‘blocks’’ of up- or down-
regulated genes that classify the Banff 0 vs. Banff 1 (mild CAN).
However, it is also evident why signatures of multiple genes are
necessary to achieve high class predictive accuracies in heterog-
enous clinical populations that are the reality of transplantation
medicine. A logical question is how many genes are actually
necessary for a robust diagnostic? We took the top 10 and top 3
genes from our consensus set for mild CAN and performed class
prediction using the DLDA method. The top 10 had a predictive
accuracy of 80%, sensitivity of 85% and specificity of 77%,
whereas the top 3 genes had a predictive accuracy of 80%,
sensitivity of 74% and specificity of 86%.
Gene expression profiling of moderate/severe CAN
Class comparisons between Banff 0 and Banff 2,3 identified
genes differentially expressed between patients without CAN and
those with moderate to severe CAN. In Test Set 1, 172 genes were
differentially expressed (p,0.005) and classified the samples by
DLDA with 78% accuracy. In Test Set 2 there were 545
differentially expressed genes. DLDA classified 95% of the samples
accurately. Functional annotation by Gene Ontology (GO) is
shown in Figure 3. A consensus analysis was done as already
described to yield 62 differentially expressed genes (p,0.005)
shared for both Test Sets of moderate/severe CAN (n=49). The
ROC curve for the top 50 genes from this consensus gene set
shows a class prediction accuracy of 92% (Figure 4A). Figure 4B
shows the Banff 0 vs. Banff 2,3 heat map using these 50 consensus
genes. An attempt to make the same predictions with only the top
10 or top 3 ranked genes was not possible using DLDA for
moderate/severe CAN.
Proteomic expression of mild and moderate/severe CAN
To investigate using proteomics to define blood cell biomarkers
for CAN, we performed shotgun tandem mass spectrometry. All
samples represented purified PBL obtained at the same time as
biopsies. We did not use the whole blood samples from Test Set 2
because high quality protein preparations cannot be obtained from
PaxGene tubes. Differential protein expression was performed
using a relative quantification strategy based on normalized
spectral counts[31].
We identified 206 differentially expressed proteins (p,0.05) for
Banff 0 vs. Banff 1 (mild CAN). In addition, we identified 135
proteins unique to Banff 0 and 167 proteins unique to Banff 1.
Class comparisons for Banff 0 vs. Banff 2,3 (moderate/severe
CAN) yielded 282 differentially expressed proteins (p,0.05) and
509 proteins unique to Banff 2,3. We found 95 proteins
differentially expressed in mild and moderate/severe CAN as
compared to Banff 0, representing candidate protein markers for
any stage of CAN. In parallel, 94 proteins were differentially
expressed only in mild CAN and these were linked to cell death,
cell signaling, and post-translational protein modifications. The
168 proteins differentially expressed only in moderate/severe
CAN were linked to cellular morphology, growth and proliferation
and signaling via ERK/MAPK, acute phase responses, IGF1 and
PPARa/RXRa.
There were 135 proteins unique to mild CAN and 322 proteins
unique to moderate/severe CAN. Both mild and moderate/severe
CAN had immune and inflammation related proteins (20 and 37,
respectively) but many of these proteins are not mapped to the
same functional pathways (e.g. calcium signaling in mild CAN and
apoptosis, NK cell and PTEN signaling for moderate/severe
CAN). In other cases, such as signaling via T and B cell receptors,
IL4 and JAK/STAT, the same canonical pathways were found
but different unique proteins were identified.
Using only the differentially expressed proteins, DLDA
obtained a 64% mean correct classification of mild CAN and an
83% correct classification for moderate/severe CAN. In contrast,
the unique proteins identified only in the blood of patients with
biopsy-documented mild (n=135) or moderate/severe CAN
(n=322), represent candidate biomarkers with a 100% class
prediction value in this data set.
We compiled the matches between proteins identified by mass
spectrometry and mRNA transcripts identified using microarrays.
The premise is that protein/transcript matches are a form of
candidate biomarker validation based on two independent
technologies. There were 11 matches for the 393 consensus genes
for mild CAN, 32 matches for the 1066 genes for mild CAN in
Blood Biomarkers for CAN/IFTA
PLoS ONE | www.plosone.org 4 July 2009 | Volume 4 | Issue 7 | e6212Figure 1. Pie charts showing the Gene Ontology annotations for both Test Sets for Banff 0 vs. Banff 1 (mild CAN). Each slice of the pie
chart represents the percentage of genes represented by that functional class. A) Test Set 1 (PBL) for Banff 0 vs. Banff 1; B) Test Set 2 (Whole Blood) for
Banff 0 vs. Banff 1. The first key point is that there is no difference in the general groups of differentially expressed, functional genes assigned in an
unbiased fashion by analysis using Gene Ontology whether we are interrogating the profiles of PBL or whole blood. The second key point is that
there are a number of genes representing different pathways connected to immune/inflammatory and tissue injury mechanisms.
doi:10.1371/journal.pone.0006212.g001
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PLoS ONE | www.plosone.org 5 July 2009 | Volume 4 | Issue 7 | e6212Figure 2. Class prediction analysis of Banff 0 vs. Banff 1 (mild CAN) based on Diagonal Linear Discriminant Analysis for the top 50
Banff 0 vs. Banff 1 consensus genes ranked by p values. A) depicts the Receiver Operating Characteristic (ROC) curves and provides the
Sensitivity, Specificity, Positive Predictive Value (PPV) and Negative Predictive Value (NPV); B) depicts the heat map classifying Banff 0 vs. Banff 1 using
the top 50 consensus genes where (red) is up-regulated and (green) is down-regulated.
doi:10.1371/journal.pone.0006212.g002
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Test Set 2. There were no matches for the 62 consensus genes for
moderate/severe CAN but 9 matches in the 172 genes for
moderate/severe CAN in Test Set 1 and 9 matches in the 545
genes for moderate/severe CAN in Test Set 2. All protein/
transcript matches are listed in Supplementary Data Table S9.
Figure 3. Pie charts showing the Gene Ontology annotations for both Test Sets for Banff 0 vs. Banff 2,3 (moderate to severe CAN).
Each slice of the pie chart represents the percentage of genes represented by that functional class. A) Test Set 1 (PBL) for Banff 0 vs. Banff 2,3; B) Test
Set 2 (Whole Blood) for Banff 0 vs. Banff 2,3. The first key point is that there is no difference in the general groups of differentially expressed,
functional genes assigned in an unbiased fashion by analysis using Gene Ontology whether we are interrogating the profiles of PBL or whole blood
(as was true for the Banff 0 vs. Banff 1 comparisons shown in Figure 1). The second key point is that the number of differentially expressed immune/
inflammatory genes is significantly less than observed in mild CAN with many more genes linked to metabolic and other pathways consistent with
the hypothesis that early stages of CAN are driven by immune/inflammatory mechanisms and tissue injury but later stages reflect slowly progressive
renal dysfunction and fibrosis.
doi:10.1371/journal.pone.0006212.g003
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PLoS ONE | www.plosone.org 7 July 2009 | Volume 4 | Issue 7 | e6212Figure 4. Class prediction analysis of Banff 0 vs. Banff 2,3 (moderate to severe CAN) based on Diagonal Linear Discriminant
Analysis for the top 50 Banff 0 vs. Banff 2,3 consensus genes ranked by p values. A) depicts the Receiver Operating Characteristic (ROC)
curves and provides the Sensitivity, Specificity, Positive Predictive Value (PPV) and Negative Predictive Value (NPV); B) depicts the heat map classifying
Banff 0 vs. Banff 2,3 using the top 50 consensus genes where (red) is up-regulated and (green) is down-regulated.
doi:10.1371/journal.pone.0006212.g004
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The primary objective of this study was the discovery of
biomarkers in the peripheral blood of kidney transplant patients
with biopsy-documented interstitial fibrosis and tubular atrophy
(IF/TA) and no known cause, which we refer to here as Chronic
Allograft Nephropathy (CAN)[14]. To this end, we purposely
integrated the results of two, independently collected sets of patient
samples that were significantly different in multiple clinical
elements. Thus, the selection of biomarker candidates is not
significantly influenced by the time of biopsy (ranging from 1 to 6
years post-transplant), the specific immunosuppressive protocols
(use of different calcineurin inhibitors vs. sirolimus) or the
technology used to purify the mRNA transcripts (density
gradient-separated cells vs. whole blood). This experimental
design was chosen for its advantages in defining a consensus set
of robust candidate biomarkers for CAN suitable for clinical use.
We acknowledge that it is likely that using more closely matched
sets of patient samples, for example, patients only 2 years post-
transplant or only one source of blood cell RNA such as the
PaxGene tubes, would result in higher total numbers of
differentially expressed candidate mRNA transcripts and proteins.
We remind the reader again that our use of PBL-derived RNA in
Test Set 1 reflected the best approach possible at a time before
whole blood RNA analysis using the PaxGene technology was
possible. However, despite these limitations, our predictions of
correct classifications for CAN based on the consensus mRNA
candidates described here for these otherwise very heterogeneous
clinical data sets are 80% for mild CAN and 92% for moderate/
severe CAN. In this context, the widely used prostate specific
antigen (PSA) biomarker, tested in an equally heterogenous
human population, was originally introduced with a predictive
value of 28–35%[34] based on the rationale that there was no
other minimally invasive option for early detection of prostate
cancer at that time, which is true for CAN today.
There are two critical questions for the design of the next study
as a prospective serial blood monitoring trial. First, we are almost
certain that restricting the analysis to whole blood samples
obtained using the PaxGene system will significantly increase the
number of consensus genes in any two test set comparison that is
done. However, while some will demand that the next study use
more standardized selection criteria for subjects (for example,
identical immunosuppressive therapy), for detailed biopsy histol-
ogy (for example, identical grades of IFTA based on the Banff
schema) and a single time point post transplant for the biopsy
evaluations, our view is that the reality of current clinical practice
is remarkably diverse and that is not going to change. In a clinical
situation, the best biomarker signature is the one least dependent
for classification accuracy on any kind of homogenous selection
criteria. What would be the general value of a set of biomarkers
that were only useful at exactly two years post-transplant or only
applicable to patients with a single grade of IFTA on the biopsy?
In that context, we believe that the current experimental design,
encompassing so much of the diversity currently present in clinical
transplantation practice in the US, is actually the best design for
biomarker discovery.
A question that cannot be answered yet is how many
biomarkers are necessary to insure a robust diagnostic test. Our
results here indicate that whole genome profiling is certainly not
necessary as we obtain very reasonable predictive accuracy,
sensitivity and specificity with 150, 100 and 50 total genes per
signature. There are now several technology platforms perfectly
suitable for point of clinical service implementation that can
measure 100 genes or more cost effectively and within hours. It
may also be possible to do such testing with even fewer genes but
we suspect that the complexity of transplant populations and
clinical phenotypes will frustrate efforts to reduce the testing
signature to such a minimal set. As for application to clinical
practice, we propose that the model will be serial, prospective
measurements of the signature at regular intervals for the life of the
kidney transplant. The absence of a positive CAN/IFTA signature
at any point in time will indicate adequate immunosuppression or
over-immunosuppression. Careful reductions in immunosuppres-
sive drug doses could then be used with repeat monitoring of the
signature to establish the optimal drug combination and level for
each patient to prevent CAN/IFTA and insure the long term
safety of the therapy.
Biomarker discovery has been done successfully using
peripheral blood profiling for acute rejection in heart transplan-
tation[35,36]. Peripheral blood studies of kidney transplant
patients with ‘‘operational tolerance’’ included 22 patients with
biopsy-documented chronic rejection[37]. Two of the genes
(DPYD, IRS2) reported to distinguish ‘‘operational tolerance’’
are identified in our consensus sets. Our earlier study of 42
kidney biopsies showed that gene expression profiles of CAN
had significant up-regulation of immune/inflammation, fibrosis
and tissue remodeling genes[16]. However, only 5 genes from
these CAN biopsies were identified in the current peripheral
blood consensus sets. A study of 11 CAN biopsies identified 3
genes linked to immunity and fibrosis that were tested by
quantitative PCR in urine and peripheral blood with good
correlations in urine but none in peripheral blood[38]. In our
study of acute rejection, candidate mRNA transcripts were
identified in both biopsies and peripheral blood, but with no
overlap[24]. Therefore, candidate gene biomarkers identified in
peripheral blood appear to be distinct from those identified in
tissue. It is not our position that gene expression profiling of the
biopsy is not useful but rather that the biopsy and the peripheral
blood are very different compartments and simple comparisons
of the two are not informative.
Urine based proteomics have been used to identify biomarkers
for acute rejection using SELDI-TOF mass spectroscopy[23,39]
but to our knowledge this is the first study to identify blood cell-
based proteomic markers for transplantation using tandem mass
spectroscopy. We have identified several hundred proteins that are
significantly differentially expressed in peripheral blood of patients
with CAN as a function of histology grade, mild to moderate/
severe. However, the group of uniquely identified proteins
potentially represents the highest value biomarker candidates
though this will require validation in another independent set of
samples. Integrating proteomics with gene expression, we
identified over 80 protein/transcript matches for CAN providing
candidate validation based on two independent technologies. On
the other hand, using the differentially expressed protein and
transcript matches did not significantly improve the classifications
obtained with the consensus gene expression set alone (data not
shown). It is important to note that in such complex clinical
samples that we can interrogate greater than 80% of the cell’s
transcriptome but only about 10% of the proteome. However,
technologies to increase the capability of tandem mass spectrom-
etry proteomics to identify and quantify candidates are rapidly
evolving and other technologies such as antibody arrays and
fluorescent bead assays are also potential platforms for clinical
implementations. Moreover, as already noted, the potential of the
uniquely expressed proteins identified for mild CAN (n=135) and
moderate/severe CAN (n=322) are to be 100% diagnostic of the
graft histology. Testing these predictions in the next study will be
of critical importance.
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compare the results of the gene expression profiles of the
transplant biopsies that were all done in parallel with the
peripheral blood gene expression profiling. The objective of this
work was to prove the hypothesis that proteogenomic profiling of
peripheral blood could yield a set of minimally invasive biomarkers
capable of diagnosing the presence and severity of CAN with high
confidence and without the necessity of an invasive kidney biopsy.
While we understand the mechanistic importance of understand-
ing the gene and protein changes in the kidney that occur with
progression of CAN, this is an entirely separate question and will
be the subject of another manuscript. The central challenge
addressed in the present study was the fidelity of proteogenomic
profiling of the blood compartment. In fact, we propose that the
peripheral blood represents a fully functional and distinct
compartment of the immune system that actively serves to traffic
and modulate all the components of effector immunity. While
clearly the tissue injury that causes the progression of CAN is
occurring in the kidney, we believe that a significant determinant
of the phenotype of the host immune response, either acceptance
of the graft or chronic rejection, is actually established and
subsequently regulated within the peripheral blood compartment,
lymph nodes and spleen.
Finally, it is important to emphasize that it was not evident to
anyone in transplantation at the beginning of our study that there
would be a molecular signature in peripheral blood cell mRNA or
cellular proteins for the chronically progressive kidney transplant
dysfunction referred to by the term CAN/IFTA. We recognized
the complications in the genetic and clinical diversity of transplant
patients, multiple clinical centers, the cellular complexity of
peripheral blood, and the impact of factors such as immunosup-
pression, environment and time post-transplant. Nonetheless, we
have discovered several hundred mRNA and proteomic biomark-
ers in peripheral blood defining unique proteogenomic signatures
and demonstrated correlations with histologically mild (80% class
prediction accuracy for top 50 gene candidates) and moderate/
severe CAN (92% class prediction accuracy for top 50 gene
candidates). Thus, this study represents a clear proof of concept for
the use of peripheral blood biomarkers as diagnostic tools for
clinical transplantation and specifically, for CAN.
We are not concluding that our current gene sets are the
optimal final candidates for clinical implementation, due to the
technical limitations discussed above created by using PBL vs.
whole blood assays. However, we do conclude that our results are
the basis for the next critical step, a prospective clinical trial in
kidney transplantation with serial blood monitoring and genome-
wide gene expression and proteomic profiling. Another key point
is that the design of the present study was all based on profiling
subjects with biopsy-proven CAN and that was the correct design
for a biomarker discovery program and an initial validation. Thus,
the evidence presented supports the conclusion that these
candidate genes are diagnostic. On the other hand, the point of
doing the serial monitoring study next with clinical and biopsy-
confirmed transplant outcomes will be to test the hypothesis that
peripheral blood gene expression profiling is also capable of
predicting the development of CAN. The importance of this next
step is that if these biomarker panels are proven to be as predictive
as they are now diagnostic, then the logical next question will be
whether we can use these gene expression signatures to manage
and optimize the efficacy and safety of immunosuppression for
patients on an individual basis. This will introduce personalized
medicine to kidney transplantation.
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